세계의 SGLT2 억제제 시장

Global SGLT2 Inhibitors Market to Reach US$29.5 Billion by 2030

The global market for SGLT2 Inhibitors estimated at US$18.4 Billion in the year 2024, is expected to reach US$29.5 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Type 2 Diabetes, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$15.5 Billion by the end of the analysis period. Growth in the Cardiovascular segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.8 Billion While China is Forecast to Grow at 7.9% CAGR

The SGLT2 Inhibitors market in the U.S. is estimated at US$4.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global SGLT2 Inhibitors Market - Key Trends & Drivers Summarized

Is Expanding Therapeutic Scope Transforming the Market Landscape for SGLT2 Inhibitors?

The global market for SGLT2 inhibitors is undergoing a major transformation, moving far beyond its original focus on glycemic control in type 2 diabetes. What began as a novel class of antidiabetic agents has now evolved into a cornerstone therapy in cardio-renal-metabolic care. Clinical trials over the last few years have consistently demonstrated that SGLT2 inhibitors such as empagliflozin, dapagliflozin, and canagliflozin deliver significant cardiovascular and renal protective effects independent of their blood glucose-lowering abilities. As a result, these drugs are increasingly being prescribed not only for type 2 diabetes but also for heart failure with reduced ejection fraction (HFrEF), chronic kidney disease (CKD), and more recently, heart failure with preserved ejection fraction (HFpEF). Regulatory bodies across the globe have responded by expanding approved indications, which is dramatically broadening the patient population eligible for these therapies. This shift marks a key inflection point in the market, as endocrinologists, cardiologists, and nephrologists begin to co-manage patients using a shared pharmacological tool. The repositioning of SGLT2 inhibitors as multi-disease agents is significantly boosting their clinical value, healthcare system relevance, and long-term market sustainability.

Can Real-World Evidence and Guideline Inclusion Propel Mainstream Adoption?

One of the most powerful drivers behind the widespread adoption of SGLT2 inhibitors is the robust body of real-world evidence and major endorsements from global clinical guidelines. Organizations such as the American Diabetes Association (ADA), European Society of Cardiology (ESC), Kidney Disease: Improving Global Outcomes (KDIGO), and the American College of Cardiology (ACC) have rapidly incorporated SGLT2 inhibitors into their treatment protocols-not only for glucose control but as first-line therapy for heart failure and CKD, even in patients without diabetes. This cross-specialty acceptance is propelling greater confidence among prescribers, leading to earlier initiation and broader use across patient profiles. Additionally, large-scale outcomes studies continue to reinforce the drug class’s benefits in reducing hospitalization for heart failure, slowing progression of kidney disease, and lowering cardiovascular mortality. These findings have been instrumental in convincing payers and formulary committees to expand reimbursement, especially in markets with value-based healthcare models. The growing repository of post-marketing surveillance data and patient registries is further validating the drugs' safety profiles, helping to dispel concerns around side effects such as diabetic ketoacidosis or genitourinary infections. This strong evidence-based foundation is making SGLT2 inhibitors one of the most rapidly adopted therapeutic classes in recent years.

Are Market Dynamics and Competitive Expansion Driving Innovation in SGLT2-Based Therapies?

The commercial success of first-generation SGLT2 inhibitors has sparked a wave of R&D and competitive activity, with pharmaceutical companies racing to extend the clinical and market footprint of the drug class. The emergence of combination therapies-such as SGLT2 inhibitors paired with DPP-4 inhibitors or GLP-1 receptor agonists-is opening new avenues for integrated diabetes and metabolic disorder management. At the same time, next-generation molecules with dual or triple inhibitory activity (e.g., SGLT1/SGLT2 inhibitors) are being developed to enhance efficacy and expand therapeutic targets. Companies are also exploring novel delivery formats, extended-release formulations, and co-formulated pills to improve patient adherence and convenience. Competitive differentiation is becoming crucial as more players enter the space, particularly in generics and biosimilars as key patents begin to expire. In addition, strategic partnerships, licensing deals, and co-marketing arrangements are on the rise, as firms look to strengthen market positioning and regional access. Geographic expansion into underserved markets-particularly in Asia-Pacific, Latin America, and the Middle East-is another key strategy, enabled by growing awareness of chronic disease prevalence and improvements in diagnostic infrastructure. As the competitive field becomes more sophisticated, innovation and market agility are defining the next growth phase for the SGLT2 inhibitors category.

What’s Fueling the Rapid Growth of the SGLT2 Inhibitors Market?

The growth in the SGLT2 inhibitors market is driven by several factors directly tied to evolving clinical guidelines, expanding indications, and healthcare infrastructure trends. First, the shift from glucose-centric prescribing to a broader focus on cardiovascular and renal protection is significantly increasing the number of eligible patients. Second, strong support from international guidelines is driving adoption across multiple specialties, making these drugs a go-to therapy for cardiologists and nephrologists as well as endocrinologists. Third, the growing global burden of type 2 diabetes, heart failure, and chronic kidney disease is expanding the need for therapies that offer multi-organ protection and long-term outcomes. Fourth, pharmaceutical innovation is extending the life cycle of the drug class through combination therapies, expanded indications, and next-generation molecules. Fifth, improved physician awareness and education programs are encouraging earlier initiation and better adherence. Sixth, payer willingness to reimburse for SGLT2 inhibitors in high-risk patients is supporting access, especially in regions with value-based care models. Seventh, digital health integration is enabling better monitoring and long-term tracking of therapy outcomes, which is helping demonstrate real-world value. Lastly, growing patient demand for oral, once-daily therapies with proven protective benefits is reinforcing the class’s appeal in chronic disease management. Together, these drivers are establishing SGLT2 inhibitors as a foundational therapy in the global fight against cardio-renal-metabolic disorders.

SCOPE OF STUDY:

The report analyzes the SGLT2 Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 39 Featured) -

• Astellas Pharma Inc.
• AstraZeneca
• Biocon Limited
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Chugai Pharmaceutical Co., Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Kissei Pharmaceutical Co. Ltd.
• Kowa Company Ltd.
• Lexicon Pharmaceuticals, Inc.
• Lexicon Pharmaceuticals, Inc.
• Lupin Limited
• Mankind Pharma Ltd
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Ono Pharmaceutical Co., Ltd.
• Pfizer
• Sanofi
• Sihuan Pharmaceutical Holdings Group Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Sun Pharmaceutical Industries Ltd
• Taisho Pharmaceutical Holdings Co.
• TheracosBio, LLC
• Torrent Pharmaceuticals Ltd
• Youngene Therapeutics Inc. Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • SGLT2 Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Diabetes and Heart Failure Prevalence Throws the Spotlight on SGLT2 Inhibitors as a Dual-Benefit Therapy
  • Expanding Evidence Base in Cardiovascular and Renal Outcomes Propels Growth Beyond Glycemic Control
  • Inclusion in Clinical Guidelines Strengthens the Business Case for Early Adoption and Prescribing Confidence
  • Growing Focus on Integrated Cardio-Renal-Metabolic Care Expands Addressable Market Opportunity
  • Increased R&D Activity and Pipeline Expansion Accelerate Demand for Combination Therapies Involving SGLT2 Inhibitors
  • Real-World Evidence and Post-Marketing Data Drive Adoption Through Demonstrated Long-Term Safety and Efficacy
  • Rising Healthcare Costs Spur Growth in Cost-Effective, Outcome-Driven Therapeutics Like SGLT2 Inhibitors
  • Growing Acceptance in Primary Care Settings Enhances Prescriber Base and Sustains Market Growth
  • Shift Toward Oral Therapies in Chronic Disease Management Drives Preference for SGLT2 Inhibitor Class
  • Increasing Awareness Among Patients and Advocacy Groups Throws the Spotlight on the Need for Holistic Disease Management
  • Focus on Personalized Medicine and Risk Stratification Drives Tailored Use of SGLT2 Inhibitors Across Patient Cohorts
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World SGLT2 Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Canada 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Japan 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: China 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: China 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for SGLT2 Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Europe 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: France 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: France 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Germany 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Germany 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Italy 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Italy 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: UK 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: UK 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Rest of Europe 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Rest of Europe 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • SGLT2 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Asia-Pacific 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Asia-Pacific 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for SGLT2 Inhibitors by Indication - Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Rest of World 15-Year Perspective for SGLT2 Inhibitors by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease and Others for the Years 2015, 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for SGLT2 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Rest of World 15-Year Perspective for SGLT2 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION